You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 8, 2024

Details for Patent: 9,649,364

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,649,364 protect, and when does it expire?

Patent 9,649,364 protects GVOKE HYPOPEN and GVOKE PFS and is included in one NDA.

This patent has twenty-one patent family members in fourteen countries.

Summary for Patent: 9,649,364

Title:	Methods for producing stable therapeutic formulations in aprotic polar solvents
Abstract:	Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.
Inventor(s):	Prestrelski; Steven (San Diego, CA), Sandoval; Michael (Austin, TX), Donovan; Martin (Austin, TX)
Assignee:	XERIS PHARMACEUTICALS, INC. (Austin, TX)
Application Number:	15/136,650
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound;

Drugs Protected by US Patent 9,649,364

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Xeris	GVOKE HYPOPEN	glucagon	SOLUTION;SUBCUTANEOUS	212097-003	Sep 10, 2019		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			TREATMENT OF SEVERE HYPOGLYCEMIA	⤷ Sign Up
Xeris	GVOKE HYPOPEN	glucagon	SOLUTION;SUBCUTANEOUS	212097-004	Sep 10, 2019		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			TREATMENT OF SEVERE HYPOGLYCEMIA	⤷ Sign Up
Xeris	GVOKE PFS	glucagon	SOLUTION;SUBCUTANEOUS	212097-001	Sep 10, 2019		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			TREATMENT OF SEVERE HYPOGLYCEMIA	⤷ Sign Up
Xeris	GVOKE PFS	glucagon	SOLUTION;SUBCUTANEOUS	212097-002	Sep 10, 2019		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			TREATMENT OF SEVERE HYPOGLYCEMIA	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,649,364

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016326749	⤷ Sign Up
Brazil	112018005800	⤷ Sign Up
Canada	2999404	⤷ Sign Up
Canada	3204984	⤷ Sign Up
China	108135980	⤷ Sign Up
China	115531523	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.